Science Corporation Secures $230 Million to Commercialize Breakthrough Vision Restoration Technology

Science Corporation announced the close of a $230 million Series C financing round on March 5, 2026. This brings total capital to approximately $490 million for the neural engineering firm based in Alameda. The new funds are designated to accelerate the commercial launch of PRIMA, a brain-computer interface designed to restore sight. The financing round saw significant participation from Lightspeed Venture Partners, Khosla Ventures, and IQT. CEO Max Hodak stated that the company aims to offer patients hope beyond the limitations of traditional medicine. By engaging the brain directly as an information processing organ, the technology drives unprecedented clinical impact. PRIMA functions as a subretinal implant that acts as artificial photoreceptors for patients with late-stage macular degeneration. Clinical results published in the New England Journal of Medicine showed 80 percent of participants gained meaningful visual acuity. This allows users to read text and recognize shapes despite advanced geographic atrophy. A commercial launch in Europe is expected later this year following a submitted CE mark application. Science Corporation is also seeking regulatory approval from the FDA for the United States market. This trajectory could make the company the first BCI provider with a functional vision restoration product available to consumers. Beyond the flagship implant, the company is expanding clinical trials to include Stargardt disease and retinitis pigmentosa. These studies will be conducted at the Sydney Eye Hospital in Australia to address inherited retinal vision loss. The capital will also support the advancement of the Biohybrid neural interface and the Vessel perfusion platform. Strategy Officer Darius Shahida noted that the company is now focused on scaling operations and achieving profitability. The vertically integrated model allows Science to control everything from chip design to external hardware. This approach mirrors the rapid iteration cycles necessary to lead the emerging neurotechnology sector.